Literature DB >> 21538981

Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces.

Ching-Seng Ang1, Julie Rothacker, Heather Patsiouras, Peter Gibbs, Antony W Burgess, Edouard C Nice.   

Abstract

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths worldwide with an annual incidence of almost a million cases and an annual mortality around 500,000. The fecal occult blood test is currently the first line method for CRC screening, but has unacceptably low sensitivity and specificity. Improved screening tests are therefore urgently required for early-stage CRC screening when therapy is most likely to be effective. We describe a discovery-based proteomics hypothesis using orthogonal multi-dimensional fractionation (1-D SDS-PAGE, RP-HPLC, size exclusion chromatography) to mine deep into the fecal proteome for the initial discovery process, which generated a library containing 108 human fecal proteins with the associated peptide and MS/MS data. These data were then used to develop and optimize a multiplex multiple reaction monitoring assay for 40 non-redundant human proteins present in the feces. To show proof of principal for clinical analysis, multiplex screening of these 40 proteins was carried out on fecal samples from eight CRC patient and seven normal volunteers. We identified 24 proteins consistently found in all samples and nine proteins found only in the CRC patients, showing the potential of this approach for the analysis of potential CRC biomarkers. Absolute quantitation using C-terminal isotopically labeled synthetic peptides corresponding to hemoglobin and carcinoembryonic antigen 5 was also performed.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21538981     DOI: 10.1002/elps.201000502

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  5 in total

Review 1.  Proteomics for discovery of candidate colorectal cancer biomarkers.

Authors:  Paula Alvarez-Chaver; Olalla Otero-Estévez; María Páez de la Cadena; Francisco J Rodríguez-Berrocal; Vicenta S Martínez-Zorzano
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

2.  MRMaid 2.0: mining PRIDE for evidence-based SRM transitions.

Authors:  Jun Fan; Fady Mohareb; Nicholas J Bond; Kathryn S Lilley; Conrad Bessant
Journal:  OMICS       Date:  2012-07-17

3.  A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers.

Authors:  Sadia Mahboob; Seong Beom Ahn; Harish R Cheruku; David Cantor; Emma Rennel; Simon Fredriksson; Gabriella Edfeldt; Edmond J Breen; Alamgir Khan; Abidali Mohamedali; Md Golam Muktadir; Shoba Ranganathan; Sock-Hwee Tan; Edouard Nice; Mark S Baker
Journal:  Clin Proteomics       Date:  2015-04-08       Impact factor: 3.988

Review 4.  A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.

Authors:  Sara S Faria; Carlos F M Morris; Adriano R Silva; Micaella P Fonseca; Patrice Forget; Mariana S Castro; Wagner Fontes
Journal:  Front Oncol       Date:  2017-02-20       Impact factor: 6.244

Review 5.  Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.

Authors:  Petra Hudler; Nina Kocevar; Radovan Komel
Journal:  ScientificWorldJournal       Date:  2014-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.